Uniao Quimica (IFC-46445)

  • Brazil
Geographic location where the impacts of the investment may be experienced.
Specific Location
Whenever identified, the area within countries where the impacts of the investment may be experienced. Exact locations of projects may not be identified fully or at all in project documents. Please review updated project documents and community-led assessments.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Stage of the project cycle. Stages vary by development bank and can include: pending, approval, implementation, and closed or completed.
Bank Risk Rating
Environmental and social categorization assessed by the development bank as a measure of the planned project’s environmental and social impacts. A higher risk rating may require more due diligence to limit or avoid harm to people and the environment. For example, "A" or "B" are risk categories where "A" represents the highest amount of risk. Results will include projects that specifically recorded a rating, all other projects are marked ‘U’ for "Undisclosed."
Voting Date
Sep 28, 2022
Date when project documentation and funding is reviewed by the Board for consideration and approval. Some development banks will state a "board date" or "decision date." When funding approval is obtained, the legal documents are accepted and signed, the implementation phase begins.
A public entity (government or state-owned) provided with funds or financial support to manage and/or implement a project.
  • Industry and Trade
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
The categories of the bank investment: loan, grant, guarantee, technical assistance, advisory services, equity and fund.
Investment Amount (USD)
$ 50.00 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Project Cost (USD)
$ 50.00 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Primary Source

Original disclosure @ IFC website

Updated in EWS Oct 18, 2022

Disclosed by Bank Aug 26, 2022

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
If provided by the financial institution, the Early Warning System Team writes a short summary describing the purported development objective of the project and project components. Review the complete project documentation for a detailed description.

União Química Farmacêutica Nacional S.A. (“UQ” or the “Company”) is among the 10th largest national pharmaceutical companies in Brazil, with more than 85 years of history. Headquartered in Sao Paulo, the Company has eight manufacturing facilities in Brazil and more than 7650 employees. UQ is focused on human health (65% of sales, mostly to the private sector), animal health (19% of sales) and 16% of sales are related to contract manufacturing, selling to top international brands.The company’s industrial capacity is composed of eight plants, including the following facilities:(i) Brasília (DF) and Pouso Alegre (MG) plants have their production directed to the Human Health Division, (ii) Embu Guaçu (SP) unit is dedicated to medicinal products for the Animal Health Division, and, (iii) the Anovis unit in Taboão da Serra (SP) and Inovat, at Guarulhos (SP), are dedicated to the outsourcing of drugs production for the pharmaceutical industry in the solid and liquid forms. The Bthek plant is intended for biotechnology. Also, the company has a graphic plant that produces cartridges, package inserts, adhesive labels, as well as working with promotional materials for the pharmaceutical industry. This facility includes a logistic center for distribution of products.   

The proposed investment consists of an 8-year secured A Loan of BRL 270 million (US$50 million) in UQ. From this, BRL 100 million will be used to upgrade two of their existing plants to be able to produce vaccines (both for COVID-19 and other uses as well). BRL 235 million will be used to increase manufacturing capacity for certain products such as antibiotics, corticoids, and anti-inflammatory, anaesthetics, among others, serving the hospital segment. Due to COVID-19, there was a spike in demand from hospitals and UQ needs to increase the capacity in 2 of their existing plants to properly serve its clients. A big portion of these investments would be related to COVID-19 related drugs. BRL 100 million would be used to install solar panels on the roofs of all its plants in Brazil, to contribute to its decarbonization plan. There will not be any new construction outside the plants (no new footprint), all investments would be within the existing plants.                            

Investment Description
Here you can find a list of individual development financial institutions that finance the project.

Contact Information
This section aims to support the local communities and local CSO to get to know which stakeholders are involved in a project with their roles and responsibilities. If available, there may be a complaint office for the respective bank which operates independently to receive and determine violations in policy and practice. Independent Accountability Mechanisms receive and respond to complaints. Most Independent Accountability Mechanisms offer two functions for addressing complaints: dispute resolution and compliance review.

Uniao Quimica Farmaceutica Nacional S/A
Fernando de Souza
Financial Manager

Av. Magalhaes de Castro, n° 4.800, Conjuntos 161/162, Edificio Continental Tower - Cidade Jardim São Paulo-SP, Brazil



You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries.


If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly,  you can submit a complaint at the link above to IFC’s Access to Information Policy Advisor, who reports directly to IFC’s Executive Vice President.




The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org.  You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/

How it works

How it works